Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 12/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 12/20 | 0.38 |
| ▸ | RELA | Q04206 | 12/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18869323 | 0.93 | THRB (0.36) | NFKB1NFKB2RELATHRB | |
| SCHEMBL20342972 | 0.85 | NFKB1 (0.40) | NFKB1NFKB2RELANR4A2CA12 | |
| SCHEMBL18869471 | 0.82 | MET (0.35) | NFKB1NFKB2RELAALOX5THRB | |
| SCHEMBL2182312 | 0.81 | CA2 (0.44) | NFKB1NFKB2RELACA12CA9 | |
| SCHEMBL18522702 | 0.79 | ELANE (0.39) | NFKB1NFKB2RELA | |
| SCHEMBL21475275 | 0.78 | NFKB1 (0.36) | NFKB1NFKB2RELA | |
| SCHEMBL18522600 | 0.77 | THRB (0.41) | THRB | |
| SCHEMBL24412119 | 0.77 | ALOX5 (0.48) | NFKB1NFKB2RELANR4A2CA12 | |
| SCHEMBL953280 | 0.74 | NPSR1 (0.47) | NFKB1NFKB2RELAALOX5 | |
| SCHEMBL21360524 | 0.73 | ALOX5 (0.42) | NFKB1NFKB2RELANR4A2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133363-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023208801-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209049-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023203043-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| EP-3933009-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-08-16 | — | — | EP | disclosed |
| EP-4056667-B1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3839008-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023066953-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022003001-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-01-06 | — | — | WO | disclosed |
| EP-3933009-A1 | LIQUID CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3428246-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3234689-B1 | LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-10457871-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2019-10-29 | — | — | US | disclosed |
| EP-3263673-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-20190185754-A1 | LIQUID-CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT | MERCK PATENT GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-9963637-B2 | Liquid crystal medium | MERCK PATENT GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| EP-3246377-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017097401-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | WO | disclosed |
| EP-2628779-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-3162875-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | Merck Patent GmbH (DE) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457871-B2 | Compounds and liquid-crystalline medium | XDH, MLX, CXCR1 | NFKB1 1850/4885NFKB2 2475/4885RELA 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.